JP2016524592A5 - - Google Patents

Download PDF

Info

Publication number
JP2016524592A5
JP2016524592A5 JP2016509455A JP2016509455A JP2016524592A5 JP 2016524592 A5 JP2016524592 A5 JP 2016524592A5 JP 2016509455 A JP2016509455 A JP 2016509455A JP 2016509455 A JP2016509455 A JP 2016509455A JP 2016524592 A5 JP2016524592 A5 JP 2016524592A5
Authority
JP
Japan
Prior art keywords
seq
icosl
specific antigen
binding molecule
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016509455A
Other languages
English (en)
Japanese (ja)
Other versions
JP6591964B2 (ja
JP2016524592A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/058276 external-priority patent/WO2014173975A1/en
Publication of JP2016524592A publication Critical patent/JP2016524592A/ja
Publication of JP2016524592A5 publication Critical patent/JP2016524592A5/ja
Application granted granted Critical
Publication of JP6591964B2 publication Critical patent/JP6591964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016509455A 2013-04-23 2014-04-23 Icoslへの治療上の標的特異的vnarドメインの単離 Active JP6591964B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361815043P 2013-04-23 2013-04-23
US61/815,043 2013-04-23
PCT/EP2014/058276 WO2014173975A1 (en) 2013-04-23 2014-04-23 Isolation of therapeutic target specific vnar domains to icosl

Publications (3)

Publication Number Publication Date
JP2016524592A JP2016524592A (ja) 2016-08-18
JP2016524592A5 true JP2016524592A5 (enExample) 2017-06-01
JP6591964B2 JP6591964B2 (ja) 2019-10-16

Family

ID=50543598

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016509450A Active JP6616284B2 (ja) 2013-04-23 2014-04-23 特異的結合分子の人工ライブラリー
JP2016509455A Active JP6591964B2 (ja) 2013-04-23 2014-04-23 Icoslへの治療上の標的特異的vnarドメインの単離

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016509450A Active JP6616284B2 (ja) 2013-04-23 2014-04-23 特異的結合分子の人工ライブラリー

Country Status (11)

Country Link
US (3) US10202438B2 (enExample)
EP (3) EP2989204B1 (enExample)
JP (2) JP6616284B2 (enExample)
KR (2) KR102320189B1 (enExample)
CN (2) CN105492610B (enExample)
AU (3) AU2014257565A1 (enExample)
BR (2) BR112015026729A2 (enExample)
CA (2) CA2909921C (enExample)
DK (1) DK2989203T3 (enExample)
RU (2) RU2015146419A (enExample)
WO (2) WO2014173959A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー
CA2953569A1 (en) 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
CN107074961A (zh) * 2014-11-03 2017-08-18 默克专利股份公司 用于生成双特异性鲨鱼可变抗体结构域的方法及其用途
EP3218411B1 (en) 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
ITUB20151014A1 (it) 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
CN107130300A (zh) * 2016-10-08 2017-09-05 深圳劲宇生物科技有限公司 一种dna编码分子库的合成方法及dna模板
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3688030B1 (en) 2017-09-27 2024-12-11 Elasmogen Ltd Specific binding molecules
US11180544B2 (en) * 2017-11-07 2021-11-23 City University Of Hong Kong Method of producing antibody fragment
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
CN111197074B (zh) * 2018-11-20 2023-08-15 深圳华大生命科学研究院 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用
US20220130494A1 (en) * 2019-02-11 2022-04-28 Neal W. Woodbury Systems, methods, and media for molecule design using machine learning mechanisms
GB201906997D0 (en) * 2019-05-17 2019-07-03 Elasmogen Ltd Conjugates
GB201908886D0 (en) * 2019-06-20 2019-08-07 Almac Discovery Ltd Anthracycline derivatives
WO2021222546A1 (en) * 2020-05-01 2021-11-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for identifying nanobodies and nanobody affinities
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
GB202020152D0 (en) 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
GB202020154D0 (en) * 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
AU2002319544B2 (en) * 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
DE602004032042D1 (de) 2003-08-27 2011-05-12 Proterec Ltd Bibliotheken rekombinanter chimärischer proteine
WO2005118629A1 (en) * 2004-06-02 2005-12-15 Diatech Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
JPWO2006003999A1 (ja) 2004-07-05 2008-07-31 財団法人化学及血清療法研究所 ヒト抗ヒトb7rp−1抗体およびその抗体フラグメント
EP1869192B1 (en) * 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
US8293233B2 (en) * 2005-03-25 2012-10-23 National Research Council Of Canada Method for isolation of soluble polypeptides
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
SG196835A1 (en) 2005-07-18 2014-02-13 Amgen Inc Human anti-b7rp1 neutralizing antibodies
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007306340A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
WO2009026638A1 (en) 2007-08-31 2009-03-05 Melbourne Health Marine-animal derived therapeutic and diagnostic agents for hepatitis b
AU2009301631A1 (en) 2008-10-06 2010-04-15 Commonwealth Scientific And Industrial Research Organisation Amyloid-beta peptide crystal structure
US20110231359A1 (en) * 2008-10-07 2011-09-22 Zap Holdings Limited Synchronization of relational databases with olap cubes
US8496933B2 (en) * 2009-11-04 2013-07-30 Laboratorios Silanes, S.A. De C.V. VHNAR anti-cytokine domains
US20140154241A1 (en) * 2010-12-03 2014-06-05 Cyclogenix Ltd Binding peptides i
WO2013167883A1 (en) * 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
CN103031304A (zh) * 2012-12-27 2013-04-10 苏州大学 一种微小rna用于调控b7-h2基因表达
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー

Similar Documents

Publication Publication Date Title
JP2016524592A5 (enExample)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
RU2015146419A (ru) Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
JP2023027258A (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
TWI604851B (zh) Il-17抗體用於製備治療強直性脊椎炎之藥物之用途
JP2011521662A5 (enExample)
CN108473563B (zh) 改进的tnf结合剂
US20170081412A1 (en) Antibody-fynomer conjugates
US20210260113A1 (en) Devices, methods, compositions and systems for the treatment of aging and age-related disorders
CN109937212A (zh) B7-h3抗体、其抗原结合片段及其医药用途
JP2019533807A5 (enExample)
US20250154255A1 (en) DOSING REGIMEN FOR BCMAx-CD3 ANTIBODIES CONSTRUCTS
JP2017522903A5 (enExample)
JP2016524463A5 (enExample)
JP2018529634A5 (enExample)
JP2018537421A5 (enExample)
JP2012518398A5 (enExample)
JP2017532952A5 (enExample)
RU2016135962A (ru) Выделенное антитело, способ его получения, выделенная нуклеиновая кислота, экспрессионная кассета, клетка-хозяин, фармацевтический и диагностический препараты, способ лечения больного, подверженного риску или страдающего от инфекции E.COLI, и способ диагностики определения инфекций E.COLI
JP2021512159A5 (enExample)
US20150125397A1 (en) Dual specific binding proteins directed against immune cell receptors and autoantigens
US20250388691A1 (en) Methods for treating lymphoma
JP2017515473A5 (enExample)
BR112021006123A2 (pt) anticorpos anti-sinucleína
JP2014501490A5 (enExample)